Analysts’ Weekly Ratings Updates for Supernus Pharmaceuticals (SUPN)

Several brokerages have updated their recommendations and price targets on shares of Supernus Pharmaceuticals (NASDAQ: SUPN) in the last few weeks:

  • 11/10/2017 – Supernus Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
  • 11/8/2017 – Supernus Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $47.00 price target on the stock. According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
  • 11/7/2017 – Supernus Pharmaceuticals was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $47.00 price target on the stock.
  • 11/6/2017 – Supernus Pharmaceuticals had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $50.00 price target on the stock, down previously from $53.00.
  • 11/3/2017 – Supernus Pharmaceuticals had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $61.00 price target on the stock.
  • 10/29/2017 – Supernus Pharmaceuticals was given a new $41.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 10/23/2017 – Supernus Pharmaceuticals was given a new $50.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 10/19/2017 – Supernus Pharmaceuticals is now covered by analysts at FBR & Co. They set a “buy” rating and a $53.00 price target on the stock. They wrote, “We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions.””
  • 9/27/2017 – Supernus Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $49.00 price target on the stock.
  • 9/26/2017 – Supernus Pharmaceuticals had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $41.00 price target on the stock.
  • 9/21/2017 – Supernus Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $50.00 price target on the stock.
  • 9/20/2017 – Supernus Pharmaceuticals had its “hold” rating reaffirmed by analysts at Janney Montgomery Scott. They now have a $47.00 price target on the stock.
  • 9/20/2017 – Supernus Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $51.00 price target on the stock.
  • 9/19/2017 – Supernus Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $49.00 price target on the stock. They wrote, “Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day.””
  • 9/19/2017 – Supernus Pharmaceuticals was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $47.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at $37.20 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12 month low of $20.55 and a 12 month high of $50.04. The firm has a market cap of $1,937.71, a P/E ratio of 35.66, a price-to-earnings-growth ratio of 1.60 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The firm’s revenue for the quarter was up 41.5% compared to the same quarter last year. analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.07 EPS for the current year.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the transaction, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $623,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. Insiders sold a total of 150,000 shares of company stock worth $7,055,350 over the last three months. Corporate insiders own 6.70% of the company’s stock.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply